Join
Live feed
·
PRReleasevia Quantisnow
Eagle Pharmaceuticals Inc. logo

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia

ByQuantisnow·Wall Street's wire, on your screen.
EGRX· Eagle Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EGRX (Eagle Pharmaceuticals Inc.) and more on Quantisnow.